Technology | Radiation Dose Management | August 19, 2015

Corindus, Unfors Raysafe Partner to Promote Radiation Protection in the Cath Lab

Joint agreement bundles RaySafe i2 real-time radiation dose monitoring system with Corindus’ CorPath vascular robotic system

Corindus, Corpath, radiation dose monitoring, cath lab, vascular robotic system

The Corindus Corpath vascular robotic system.

Unfors RaySafe, RaySafe i2, real-time radiation dose monitoring system

Unfors Raysafe's i2 real-time dose monitoring badge system

August 19, 2015 – Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement allowing Corindus to offer the RaySafe i2 real-time radiation dose monitoring system in conjunction with the CorPath System. This alignment enables catheterization lab physicians and staff to better protect themselves from, and monitor for, excessive radiation exposure.

The interventional cardiology field is increasingly concerned about the cumulative effects of radiation exposure on physicians and cath lab staff as more studies emerge and stories of individuals who have been forced to leave practice become more prevalent. Top of FormBottom of FormThe The 95 percent radiation exposure reduction afforded by the CorPath System’s radiation shielded cockpit increases protection for interventional cardiologists, while the RaySafe i2 badge worn by cath lab workers displays radiation exposure levels in real-time; this allows the team to be more aware of exposure levels and take steps to minimize exposure, while continuing to deliver a high standard of care.

Spectrum Health System, based in Grand Rapids, Michigan, is one of the first facilities in the United States to install and jointly utilize the CorPath System and RaySafe i2. “We take significant measures to protect our patients, and through the addition of these products, we can do the same for our physicians and cath lab staff,” stated Ryan Madder, M.D., interventional cardiologist at Spectrum Health. “Having integrated the products into my daily practice, I am more aware of both my own exposure levels and that of my team. I appreciate how these technologies can significantly change our behaviors and put us in a safer position to perform procedures.”

For more information:,

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init